Stem cell therapy restores arm, hand movement for paralyzed man : medicalnewstoday

as informed in medicalnewstoday

Stem cell therapy restores arm, hand movement for paralyzed man

Stem cell therapy restores arm, hand movement for paralyzed man

A 21-year-old man left paralyzed after a spinal cord injury has regained the use of his arms and hands, thanks to an experimental stem cell treatment performed by researchers from the Keck Medical Center at the University of Southern California.Researchers have restored arm and hand function to a paralyzed man with injections of an agent called AST-OPC1.Researchers have restored arm and hand function to a paralyzed man with injections of an agent called AST-OPC1.


additionally news-medical

UTHealth receives DOD award to investigate stem cell therapy in adults with TBI

UTHealth receives DOD award to investigate stem cell therapy in adults with TBI

A research team led by Charles S. Cox, Jr., M.D., at The University of Texas Health Science Center at Houston (UTHealth) has been awarded $6.8 million from the U.S. Department of Defense (DOD) to assess the safety and efficacy of using autologous stem cell therapy in adults with emergent traumatic brain injury.Memorial Hermann-Texas Medical Center is the site for the study."The DOD award will fund our next phase of clinical trials using cellular therapy for severe traumatic brain injury and we are gratified to see continued progress supported by our partners in the Joint Warfighter Program," said Cox, the George and Cynthia Mitchell Distinguished Chair in Neurosciences at UTHealth, professor in the Department of Pediatric Surgery and co-director of the Memorial Hermann Red Duke Trauma Institute.


let alone cancerresearchuk

Extra chemo boosts immune cell therapy in lymphoma

Extra chemo boosts immune cell therapy in lymphoma

Using two chemotherapy drugs instead of one may boost the effectiveness of a type of immune cell therapy, according to a new US study."This is important because it will help guide the design of future trials using these specialised T cells" - Professor John Anderson, UCL Great Ormond Street Institute of Child Health.The early clinical trial showed better responses and improved short-term survival in patients with non Hodgkin lymphoma given the combined treatments.